GlassScriptPhysician profile
Crystal E Humphries
NPI 1700882131
$7,086.42
in general payments reported to CMS, 2019-2025
48 companies · $1,699 in 2025
The $1,699 reported for 2025 was more than what 92% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $132 · 2022: $1,300 · 2023: $2,375 · 2024: $1,580 · 2025: $1,699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,390 · Education: $265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,390.01 |
| Education | $264.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $754.42 | 2021-2025 | Darzalex, Imbruvica, Tecvayli |
| Celgene Corporation | $751.88 | 2022-2025 | Reblozyl, Pomalyst, Opdivo |
| Incyte Corporation | $652.32 | 2021-2025 | Pemazyre, Jakafi, Monjuvi |
| Eisai INC. | $478.81 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $455.91 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $407.40 | 2022-2025 | Calquence, Tagrisso, Lynparza |
| Merck Sharp & Dohme LLC | $333.88 | 2022-2025 | Keytruda, Welireg, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $281.29 | 2022-2025 | Opdivo, Opdualag |
| Abbvie INC. | $260.77 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $244.37 | 2022-2025 | Iclusig, Fruzaqla, Alunbrig |
| Daiichi Sankyo INC. | $186.05 | 2024-2025 | Enhertu, Injectafer, Datroway |
| Genzyme Corporation | $162.06 | 2022-2024 | |
| Beigene USA, INC. | $152.79 | 2022-2025 | Brukinsa, Tevimbra |
| Seagen INC. | $128.26 | 2022-2023 | Adcetris, Tukysa, Padcev |
| Karyopharm Therapeutics INC. | $112.72 | 2022-2025 | Xpovio |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $111.20 | 2022-2023 | Lumakras |
| Pfizer INC. | $110.27 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $107.09 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $106.31 | 2022-2025 | |
| Lilly USA, LLC | $106.01 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Glaxosmithkline, LLC. | $103.50 | 2022-2025 | Ojjaara, Jemperli, Zejula |
| Pharmacyclics LLC, An Abbvie Company | $94.98 | 2023 | Imbruvica |
| Kite Pharma, INC. | $92.90 | 2022-2023 | Yescarta |
| Sobi, INC | $88.12 | 2024-2025 | |
| G1 Therapeutics, INC. | $77.34 | 2022-2023 | Cosela |
| Exelixis INC. | $68.09 | 2022-2024 | Cabometyx |
| Genentech USA, INC. | $67.95 | 2022-2025 | Venclexta, Polivy, Itovebi |
| Ipsen Biopharmaceuticals, INC | $58.36 | 2022 | |
| Taiho Oncology, INC. | $49.14 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.67 | 2025 | |
| Beone Medicines USA, INC. | $40.89 | 2025 | Tevimbra, Brukinsa |
| Alexion Pharmaceuticals, INC. | $37.52 | 2022 | |
| Aveo Pharmaceuticals, INC. | $32.50 | 2023-2024 | Fotivda |
| Astellas Pharma US INC | $32.12 | 2022-2025 | Padcev |
| Servier Pharmaceuticals LLC | $31.06 | 2024-2025 | |
| Emd Serono, INC. | $29.95 | 2023 | Tepmetko |
| Mirati Therapeutics, INC. | $26.36 | 2023 | Krazati |
| Cti Biopharma Corp. | $21.84 | 2023 | Vonjo |
| Azurity Pharmaceuticals, INC. | $21.74 | 2024 | Vivimusta |
| Rigel Pharmaceuticals, INC. | $20.88 | 2023 | Rezlidhia, Tavalisse |
| Pharmaessentia USA Corporation | $19.83 | 2024 | Besremi |
| Geron Corporation | $19.57 | 2025 | Rytelo |
| Deciphera Pharmaceuticals INC. | $19.26 | 2023 | Qinlock |
| Syndax Pharmaceuticals, INC. | $19.06 | 2025 | |
| Array Biopharma INC | $16.95 | 2025 | Mektovi, Braftovi, Lorbrena |
| Regeneron Healthcare Solutions, INC. | $16.79 | 2025 | Libtayo |
| Adc Therapeutics America, INC. | $16.75 | 2025 | |
| Adaptive Biotechnologies Corporation | $15.49 | 2024 | Clonoseq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Humphries listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.